$Pistol Pete$, $Mick$ & Friends Stock Picks /news, DD and charts

[Regis999]

Arch Therapeutics, Inc. ARTH



Faster, Safer, Simpler Surgery




The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund



A LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE !!!


Arch Therapuetics has Initiated Human Clinical Trials in Europe--200 potential applications including Pressure Ulcers (bedsores) 2.5 million cases USA with Annual Cost $10 Billion



o Arch is a small public company with a medical device pathway, relatively low capital requirements and potentially high margin novel products targeting large growing markets. Expect first product approval in 2016.


o Arch Medical Device: A LIQUID noncoagulant homostatic agent known as “AC5.” Works in presence of “blood thinners.”



Arch Therapeutics, Inc. is a medical device company developing totally disruptive technology to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Scientists at Massachusetts Institute of Technology invented this universal fix-all hemostat that works in a few seconds.



The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with potentially up to 60% savings in time of surgery. Spray AC5 on a bleeding artery and the bleeding stops without mechanical pressure being needed in seconds. This is disruptive industry technology.



AC5 stops bleeding promptly. AC5, is desperately needed by soldiers ("13 Hours"), surgery patients, those with foot ulcers or even bedsores (A $ 10 Billion US market). The Company has identified over 200 potential areas where AC5 could be used.



The Cheapest Medical Device Stock I've Ever Seen By Michael Murphy CFA

http://seekingalpha.com/article/3286585-the-cheapest-medical-device-stock-ive-ever-seen



Human Clinical trials have begun in Europe. Total Europe and USA trial cost $10 to $14 million---tiny for Biotech company !!



Watch CEO Dr. Terrence Norchi's presentation on 2/22/16 http://wsw.com/webcast/seethru15/arth



COMPANY Website http://www.archtherapeutics.com/



COMPANY Presentation ---Page 20 Pressure Ulcers (bedsores) -2.5 million cases USA Annual Cost $10 Billion



http://content.stockpr.com/archtherapeutics/media/a615ba3d0a9c00b0e77d846e84303000.pdf



Company Video

Arch Therapuetic AC5 Surgical Hemostatic Device



Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it

Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)

Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes

Stops bleeding promptly

Faster time to stop bleeding versus five different popular marketed products

Blood thinner agnostic—only hemostasis product that is.

Efficacy even in presence of “blood thinners”
Bioasborbable

Natural amino acids, non-animal

Enables normal healing

Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer

Stores at room temperature

Indefinite shelf life

Simple, effective, versatile, safe universal





There are many other hemostatic agents, but:

* They all rely on using the patient's blood,

*They all take minutes to stop bleeding, not seconds

* None of them create a clear seal that a surgeon can see through

* None of them work just as well on people on blood thinners

* None of them work in every situation where bleeding has to be stopped

Arch's AC5 product solves all these problems